Professor Nicola Valeri reacts to being presented with an award for significant contributions to translational research, at the NCRI 2019 conference in Glasgow.
Professor Collins’ work hugely benefits from collaborating with others – including cancer biologists within the Cancer Therapeutics Unit and industrial partners.
Dr Amanda Swain is Head of the Tumour Profiling Unit at the ICR, providing access to state-of-the-art sequencing technologies and unrivalled expertise in the molecular characterisation of tumours.
Professor Harrington has a track record of successful industry partnerships, and is open to approaches for the collaborative development of candidate drugs and agents.
Dr Natrajan’s team has already uncovered genomic alterations that are specific to aggressive forms of breast cancer. She is now looking to form partnerships with industry to find ways to target these with new therapies.
At any one time, researchers in the DDU are leading around 50 first-in-human clinical studies, including many sponsored by pharmaceutical companies.
Dr Amanda Swain leads the ICR’s Tumour Profiling Unit, which is a state-of-the-art centre designed to accelerate progress towards precision medicine.
Leukaemia researchers from around the world gathered at the Royal Society last week to celebrate Professor Sir Mel Greaves and his knighthood for his services to children's leukaemia research.
For Childhood Cancer Awareness Month, PhD student Antonio Romo-Morales talks about his research in a rare children's cancer called Ewing sarcoma.